Clinical trial · Interventional
EN3285 for the Prevention or Delay of Oral Mucositis in Patients With Head and Neck Cancer
A Phase 3, Multi-center, Randomized, Double-Blind, Placebo- Controlled Study to Assess the Efficacy and Safety of EN3285 for the Prevention or Delay to Onset of Severe Oral Mucositis in Patients With Head and Neck Cancer Receiving Chemoradiotherapy
NCT00574860CI-TRIAL-00012257terminatedPhase 3ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Why stopped (as posted): Additional research
Summary
Brief summary (as posted)
Randomized, double-blind, placebo-controlled study for the treatment of head and neck cancer(HNC), to assess the ability of EN3285 to prevent or delay the onset of severe oral mucositis(OM).
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Head and Neck Cancer | Malignant Head and Neck Neoplasm | ALIAS | 0.90 |
| Oral Mucositis | — | UNRESOLVED | — |
Interventions
Interventions (3)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| EN3285 | Drug | — | UNRESOLVED |
| Placebo | Drug | — | UNRESOLVED |
| Standard of care | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (3)
- type
- EXPERIMENTAL
- label
- EN3285 (NAC ProGelz)
- description
- The EN3285 arm is the product under development
- interventionNames
- Drug: EN3285
- type
- PLACEBO_COMPARATOR
- label
- No active ingredients (placebo)
- description
- This will be an oral product that contains no active ingredient
- interventionNames
- Drug: Placebo
- type
- OTHER
- label
- Standard of Care
- description
- This arm will reflect the typical standard of care for the patient
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Significant Inclusion Criteria: * 18 years and older * newly diagnosed SCC of the oral cavity and/or oropharynx, and are intended for treatment with ChemoRT. * Have a clinical plan to receive a minimum of 60 Gy to the oral cavity and/or oropharynx * Chemotherapy: cisplatin * Have a WBC ≥3500 per cubic millimeter * Have a platelet count ≥100,000 per cubic millimeter * Have adequate renal function as determined by the principal investigator prior to enrollment * Are willing and able to undergo oral assessments * Have a Karnofsky Performance Status score ≥70 Significant Exclusion Criteria: * Have OM or other oral conditions at study entry * Plan to use Amifostine, Pilocarpine, Cevimeline or Bethanechol * Are using a pre-existing feeding tube for nutritional support at study entry * Plan to use any drug for the treatment or prevention of OM * Have had any prior radiotherapy to the head and neck * Have had prior chemotherapy within 6 months preceding enrollment * Plan to have concurrent chemotherapy, other than those regimens specified under inclusioncriteria * Have received other investigational drugs in the 30 days preceding initiation of study drug or during administration of study drug * Have medical conditions that require the use of chronic steroid therapy * Have the inability to undergo repeat treatments,
References
Publications (0)
Data not yet available
No reference posted for this study.